EPHA5 mutation predicts the durable clinical benefit of immune checkpoint inhibitors in patients with lung adenocarcinoma
Weimei Huang, Anqi Lin, Peng Luo, Yuchen Liu, Wentao Xu, Weiliang Zhu, Ting Wei, Qingwen Lyu, Linlang Guo, Jian Zhang
Topics & Concepts
ImmunotherapyAdenocarcinomaImmune systemMutationCancer researchOncologyMedicineLung cancerCancerInternal medicineImmunologyGeneBiologyGeneticsCancer Immunotherapy and BiomarkersLung Cancer Treatments and MutationsEpigenetics and DNA Methylation